Table of Contents
MALVERN, Pa. — Endo Health Solutions Inc. has appointed Don DeGolyer as chief operating officer of pharmaceuticals, which includes the company’s Endo Pharmaceuticals and Qualitest business units.
Endo said Monday that DeGolyer is slated to start as COO on Aug. 1.
"Don is a uniquely qualified, seasoned leader with nearly three decades of experience in the health care industry," stated Rajiv De Silva, president and chief executive officer of Endo Health Solutions. "Don has broad experience in both branded and generic pharmaceuticals, and I have tremendous confidence in his ability to drive operational excellence and growth."
Most recently, DeGolyer was president and CEO of Sandoz Inc., Novartis’ North America generic drug unit. Before joining Novartis in 2002, he spent 11 years at Johnson & Johnson in various roles of increasing responsibility, including vice president of marketing and sales and began his career at Pfizer Inc.
"I am extremely excited to join Rajiv and the other members of the Endo team as the company enters a new phase of growth and expansion," commented DeGolyer. "I believe that Endo is in an excellent position to deliver value to customers, employees and shareholders over the near term, and I look forward to being a part of this exciting transformation."
